This prospective randomized trial investigated dose intensification with ustekinumab in Crohn’s disease patients experiencing secondary loss of response. Two regimens – intravenous reinduction plus either every 4-week or every 8-week subcutaneous maintenance dosing – were compared over 48 weeks. Steroid-free clinical remission rates were low and statistically similar between groups, with comparable safety profiles.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
